SCHEMBL14718593

SCHEMBL14718593

FC(F)(F)c1ccc(C#Cc2cc(OCc3ccccc3)c(OCc3ccccc3)nn2)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.41
MRGPRX4 Q96LA9 4/20 0.40
HTR2C P28335 1/20 0.40
SLC6A4 P31645 1/20 0.40
HTR2B P41595 1/20 0.40
PPIA P62937 2/20 0.39
LRRK2 Q5S007 2/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
PTPN2 P17706 2/20 0.37
PTPN1 P18031 2/20 0.37
PTPN6 P29350 2/20 0.37
HPGD P15428 1/20 0.37
PTPRC P08575 1/20 0.36
PTPRB P23467 1/20 0.36
PTPN11 Q06124 1/20 0.36
CYP2C9 P11712 1/20 0.36
PTGER1 P34995 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14719605 0.84 HTR2C (0.40) MRGPRX4HTR2CSLC6A4HTR2BPPIA
SCHEMBL14719354 0.84 CYP11B1 (0.38) MRGPRX4HTR2CSLC6A4HTR2BPPIA
SCHEMBL14719322 0.83 GRM5 (0.45) MRGPRX4HTR2CSLC6A4HTR2BPPIA
SCHEMBL14719052 0.83 MRGPRX4 (0.44) MRGPRX4
SCHEMBL14729703 0.81 MRGPRX4 (0.43) LIPEMRGPRX4HTR2CSLC6A4HTR2B
SCHEMBL14718975 0.81 MRGPRX4 (0.39) MRGPRX4RXRARXRBRXRGSLC6A9
SCHEMBL28049962 0.81 L3MBTL1 (0.39) LIPEMRGPRX4RXRARXRBRXRG
SCHEMBL14719348 0.81 MRGPRX4 (0.43) MRGPRX4RXRARXRBRXRGPTGER1
SCHEMBL14719454 0.79 L3MBTL1 (0.41) LIPEPTPN1PTPN6PTPN11
SCHEMBL14719169 0.77 MAPT (0.40) PTPN1PTPN6PTPN11PTGER1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-01-07 US disclosed
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-13 US disclosed
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-13 US disclosed
US-11129828-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-09-28 US disclosed
US-11129828-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-09-28 US disclosed
US-20200121678-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2020-04-23 US disclosed
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-11-05 US disclosed
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-11-05 US disclosed
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-28 US disclosed
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-28 US disclosed
US-9290456-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-03-22 US disclosed
EP-2748149-B1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2015-10-21 EP disclosed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US disclosed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US disclosed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US disclosed
EP-2748149-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2014-07-02 EP disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed
WO-2013027000-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed
WO-2013027000-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052281-A1 NOVEL COMPOUNDS ABCG2, F12, UGT1A1 LIPE 2904/4885MRGPRX4 97/4885HTR2C 995/4885
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD LIPE 2586/4885MRGPRX4 1286/4885HTR2C 643/4885
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD LIPE 2586/4885MRGPRX4 1286/4885HTR2C 643/4885
US-20200121678-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD LIPE 2586/4885MRGPRX4 1286/4885HTR2C 643/4885
US-11129828-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD LIPE 2586/4885MRGPRX4 1286/4885HTR2C 643/4885
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD LIPE 2586/4885MRGPRX4 1286/4885HTR2C 643/4885
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD LIPE 2586/4885MRGPRX4 1286/4885HTR2C 643/4885
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD LIPE 2586/4885MRGPRX4 1286/4885HTR2C 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.